Non-canonical Hh signalling through Smoothened controls cytotoxic T cell migration in the tumor microenvironment
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
American Association for the Advancement of Science
Cancer Research Uk Cambridge Institute
https://doi.org/10.1126/sciimmunol.adr3127
Cancer Research Uk Cambridge Institute
https://doi.org/10.1126/sciimmunol.adr3127
Abstract
Description
The Hedgehog (Hh) signalling pathway is aberrantly regulated in cancer. Hh inhibitors are successful in treating basal cell carcinoma (BCC) and SHH-driven medulloblastoma but have largely failed in clinical trials of other solid cancers. We show that Hh inhibitor-treatment specifically diminishes CD8 T cell migration into the tumour microenvironment, both in murine cancer models and resected BCCs from patients treated with the Smoothened (SMO) inhibitor vismodegib. Using small molecule antagonists and genetic knockout models of key Hh signalling components, we demonstrate that the migration defect is mediated exclusively by the signal transducer Smo and not Hh ligands or Gli transcription factors. Smo acts non-canonically as a GPCR to regulate the migration of murine and human CD8 T cells via RhoA. Our data establishes the first link between Hh inhibition in vivo and the anti-tumour immune response and provides the basis for improved Hh targeting approaches for cancer patients.
Funding: This work was supported by Cancer Research UK (MdlR, A22257), a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (MdlR [107609/Z/15/Z]), a Wellcome Trust Discovery Award (MdlR [227432/Z/23/Z]) and the Addenbrooke’s Charitable Trust (KF and MdlR, Ref: 03/18 (v), Charity No.1170103). SL was funded by the Cambridge School of Clinical Medicine, Frank Edward Elmore Fund and the Medical Research Council Doctoral Training Partnership MR/N013433/1 (RG86932). OC and ACM were funded by a Cancer Research UK core grant (A17197).
Funding: This work was supported by Cancer Research UK (MdlR, A22257), a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (MdlR [107609/Z/15/Z]), a Wellcome Trust Discovery Award (MdlR [227432/Z/23/Z]) and the Addenbrooke’s Charitable Trust (KF and MdlR, Ref: 03/18 (v), Charity No.1170103). SL was funded by the Cambridge School of Clinical Medicine, Frank Edward Elmore Fund and the Medical Research Council Doctoral Training Partnership MR/N013433/1 (RG86932). OC and ACM were funded by a Cancer Research UK core grant (A17197).